G1 Therapeutics Inc [GTHX] stock is trading at $2.99, up 7.17%. An important factor to consider is whether the stock is rising or falling in short-term value. The GTHX shares have gain 16.34% over the last week, with a monthly amount glided 2.05%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
G1 Therapeutics Inc [NASDAQ: GTHX] stock has seen the most recent analyst activity on January 30, 2023, when JP Morgan upgraded its rating to a Neutral and also boosted its price target to $10 from $7. Previously, Needham reaffirmed its Buy rating on January 03, 2023, and dropped its price target to $31. On November 04, 2021, downgrade downgraded it’s rating to Underweight and revised its price target to $19 on the stock. JP Morgan downgraded its rating to a Neutral and reduced its price target to $20 on September 30, 2021. Raymond James downgraded its rating to Outperform for this stock on November 17, 2020. In a note dated June 26, 2020, ROTH Capital initiated an Buy rating and provided a target price of $55 on this stock.
G1 Therapeutics Inc [GTHX] stock has fluctuated between $1.08 and $6.14 over the past year. Currently, Wall Street analysts expect the stock to reach $4.5 within the next 12 months. G1 Therapeutics Inc [NASDAQ: GTHX] shares were valued at $2.99 at the most recent close of the market. An investor can expect a potential return of 50.5% based on the average GTHX price forecast.
Analyzing the GTHX fundamentals
G1 Therapeutics Inc [NASDAQ:GTHX] reported sales of 84.04M for the trailing twelve months, which represents a growth of 11.82%. Gross Profit Margin for this corporation currently stands at 0.92% with Operating Profit Margin at -0.27%, Pretax Profit Margin comes in at -0.33%, and Net Profit Margin reading is -0.36%. To continue investigating profitability, this company’s Return on Assets is posted at -0.3, Equity is 0.19 and Total Capital is -0.33. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.55.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.86 points at the first support level, and at 2.73 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.09, and for the 2nd resistance point, it is at 3.19.
Ratios To Look Out For
For context, G1 Therapeutics Inc’s Current Ratio is 2.94. On the other hand, the Quick Ratio is 2.55, and the Cash Ratio is 0.61. Considering the valuation of this stock, the price to sales ratio is 1.86, the price to book ratio is 5.63.
Transactions by insiders
Recent insider trading involved Bailey John E. (Jack) Jr., President and CEO, that happened on Jul 05 ’24 when 7662.0 shares were sold. Chief Business Officer, Avagliano Mark completed a deal on Jul 05 ’24 to sell 2638.0 shares. Meanwhile, Chief Operating Officer MURDOCK TERRY L sold 2475.0 shares on Jul 05 ’24.
